Table 2. Adjusted RI estimated by SCCS and excess cases per 100,000 vaccinated by vaccine product and risk intervals: 346 myocarditis/pericarditis events in the BNT162b2 and 95 events in the mRNA-1273 vaccinated population aged 12–39 years from 27 December 2020 to 30 September 2021.
| Risk interval | Dose | BNT162b2 (n. 346) | mRNA-1273 (n. 95) | ||||
|---|---|---|---|---|---|---|---|
| Events in the risk interval (n) | Adjusted RI (95% CI)* | Excess cases per 100,000 vaccinated (95% CI)** | Events in the risk interval (n) | Adjusted RI (95% CI)* | Excess cases per 100,000 vaccinated (95% CI)** | ||
| [0–21) | Dose 1 | 35 | 1.08 (0.70–1.67) | 15 | 2.22 (1.00–4.91) | 1.8 (−0.2–3.7) | |
| Dose 2 | 39 | 1.99 (1.30–3.05) | 1.0 (0.3–1.7) | 25 | 2.63 (1.21–5.71) | 4.2 (0.8–7.2) | |
| [0–7) | Dose 1 | 14 | 1.27 (0.70–2.31) | 11 | 6.55 (2.73–15.72) | 2.0 (0.8–3.6) | |
| Dose 2 | 22 | 3.39 (2.02–5.68) | 0.8 (0.4–1.4) | 23 | 7.59 (3.26–17.65) | 5.5 (3.0–7.9) | |
| [7–14) | Dose 1 | 10 | 0.92 (0.46–1.82) | 3 | 1.58 (0.45–5.58) | ||
| Dose 2 | 7 | 1.07 (0.50–2.30) | 0 | — | |||
| [14–21) | Dose 1 | 11 | 1.09 (0.56–2.12) | 1 | 0.49 (0.06–4.07) | ||
| Dose 2 | 10 | 1.58 (0.78–3.21) | 2 | 0.71 (0.17–3.09) | |||
| Ref. | 272 | 1.0 | 55 | 1.0 | |||
*Adjusted by calendar period.
**Excess cases are not given when the 95% CI of RI included the null effect.
CI, confidence interval; n., number; Ref., reference period (unexposed period); RI, relative incidence; SCCS, self-controlled cases series.